Paraneoplastic Thrombocytosis in Ovarian Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear. METHODS: We analyzed clinical data on 619 patients with epithelial ovarian cancer to test associations between platelet counts and disease outcome. Human samples and mouse models of epithelial ovarian cancer were used to explore the underlying mechanisms of paraneoplastic thrombocytosis. The effects of platelets on tumor growth and angiogenesis were ascertained. RESULTS: Thrombocytosis was significantly associated with advanced disease and shortened survival. Plasma levels of thrombopoietin and interleukin-6 were significantly elevated in patients who had thrombocytosis as compared with those who did not. In mouse models, increased hepatic thrombopoietin synthesis in response to tumor-derived interleukin-6 was an underlying mechanism of paraneoplastic thrombocytosis. Tumor-derived interleukin-6 and hepatic thrombopoietin were also linked to thrombocytosis in patients. Silencing thrombopoietin and interleukin-6 abrogated thrombocytosis in tumor-bearing mice. Anti-interleukin-6 antibody treatment significantly reduced platelet counts in tumor-bearing mice and in patients with epithelial ovarian cancer. In addition, neutralizing interleukin-6 significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer. The use of an antiplatelet antibody to halve platelet counts in tumor-bearing mice significantly reduced tumor growth and angiogenesis. CONCLUSIONS: These findings support the existence of a paracrine circuit wherein increased production of thrombopoietic cytokines in tumor and host tissue leads to paraneoplastic thrombocytosis, which fuels tumor growth. We speculate that countering paraneoplastic thrombocytosis either directly or indirectly by targeting these cytokines may have therapeutic potential. (Funded by the National Cancer Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Platelets can extravasate into the primary ovarian tumor and induce proliferation and resistance to chemotherapy (Cho et al., 2012; Stone et al., 2012; Hu et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Stone et al., 2012
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma
Thaker, P. H., Han, L. Y., Kamat, A. A., Arevalo, J. M., Takahashi, R., Lu, C., Jennings, N. B., Armaiz-Pena, G., Bankson, J. A., Ravoori, M., et al. (2006) · Nature Medicine · doi:10.1038/nm1447 · Cited by 1,320
Self-citationPlatelet α-granules: Basic biology and clinical correlates
Blair, P., & Flaumenhaft, R. (2009) · Blood Reviews · doi:10.1016/j.blre.2009.04.001 · Cited by 1,157
Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer
Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., Urbauer, D., Pennacchio, L. A., Cheng, J.-F., Nick, A. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803785 · Cited by 712
Self-citationInterleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
Kaser, A., Brandacher, G., Steurer, W., Kaser, S., Offner, F. A., Zoller, H., Theurl, I., Widder, W., Molnar, C., Ludwiczek, O., et al. (2001) · Blood · doi:10.1182/blood.v98.9.2720 · Cited by 667
Aspirin Use and Survival After Diagnosis of Colorectal Cancer
Chan, A. T. (2009) · JAMA · doi:10.1001/jama.2009.1112 · Cited by 557
Lineage-Specific Hematopoietic Growth Factors
Kaushansky, K. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052706 · Cited by 509
Stress hormone-mediated invasion of ovarian cancer cells
Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., Li, Y., Gershenson, D. M., Lutgendorf, S., & Cole, S. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1698 · Cited by 491
Self-citationRegulation of Tumor Angiogenesis by EZH2
Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozbun, L., Armaiz-Pena, G. N., Hu, W., Stone, R. L., Munkarah, A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.016 · Cited by 399
Self-citationInterleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
Self-citation
Research works printed but not linked: 2
- Riess L, 1872, Arch Anat Physiol Wissensch Med, 39, 237
- Akl EA, 2007, Cochrane Database Syst Rev, 3, CD006652
Cited by
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Self-citationHarnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Self-citationDiem, S., Schmid, S., Krapf, M., Flatz, L., Born, D., Jochum, W., Templeton, A. J., & Früh, M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.024 · Cited by 986
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
McAllister, S. S., & Weinberg, R. A. (2014) · Nature Cell Biology · doi:10.1038/ncb3015 · Cited by 966
Templeton, A. J., Ace, O., McNamara, M. G., Al-Mubarak, M., Vera-Badillo, F. E., Hermanns, T., Šeruga, B., Ocaña, A., Tannock, I. F., & Amir, E. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0146 · Cited by 719
Platelets at the interface of thrombosis, inflammation, and cancer
Franco, A. T., Corken, A., & Ware, J. (2015) · Blood · doi:10.1182/blood-2014-08-531582 · Cited by 691
The Platelet Lifeline to Cancer: Challenges and Opportunities
Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V., & Sood, A. K. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.002 · Cited by 638
Self-citationPerioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556
Platelets guide the formation of early metastatic niches
Labelle, M., Begum, S., & Hynes, R. O. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411082111 · Cited by 555
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
Cancer-associated venous thromboembolism
Khorana, A. A., Mackman, N., Falanga, A., Pabinger, I., Noble, S., Ageno, W., Moik, F., & Lee, A. Y. Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00336-y · Cited by 470
Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients
Yamamoto, T., Kawada, K., & Obama, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158002 · Cited by 445
Cancer-associated pathways and biomarkers of venous thrombosis
Hisada, Y., & Mackman, N. (2017) · Blood · doi:10.1182/blood-2017-03-743211 · Cited by 443
Interleukin-6 as a Therapeutic Target
Rossi, J.-F., Lu, Z.-Y., Jourdan, M., & Klein, B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2291 · Cited by 366
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
Hou, J., Karin, M., & Sun, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00459-9 · Cited by 366
Banerjee, S., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 357
Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets
Best, M. G., Sol, N., In ‘t Veld, S. G. J. G., Vancura, A., Muller, M., Niemeijer, A.-L. N., Fejes, A. V., Tjon Kon Fat, L.-A., Huis In ‘t Veld, A. E., Leurs, C., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.004 · Cited by 343
The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling
Grozovsky, R., Begonja, A. J., Liu, K., Visner, G., Hartwig, J. H., Falet, H., & Hoffmeister, K. M. (2015) · Nature Medicine · doi:10.1038/nm.3770 · Cited by 336
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis
Rachidi, S., Metelli, A., Riesenberg, B., Wu, B. X., Nelson, M. H., Wallace, C., Paulos, C. M., Rubinstein, M. P., Garrett-Mayer, E., Hennig, M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7911 · Cited by 335
Function and regulation of IL‐1α in inflammatory diseases and cancer
Malik, A., & Kanneganti, T. (2018) · Immunological Reviews · doi:10.1111/imr.12615 · Cited by 327
Yang, L., Moss, T., Mangala, L. S., Marini, J., Zhao, H., Wahlig, S., Armaiz‐Pena, G., Jiang, D., Achreja, A., Win, J., et al. (2014) · Molecular Systems Biology · doi:10.1002/msb.20134892 · Cited by 326
“Mice were randomly divided into two groups (n = 5 mice per group) and treated with control and GLS1 siRNA incorporated in neutral nanoliposomes (DOPC; i.p. administration; Landen et al, 2005; Stone et al, 2012): (i) control siRNA-DOPC and (ii) GLS1 siRNA-DOPC.”
MethodSelf-citationXu, X. R., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 325
Platelets and cancer: a casual or causal relationship: revisited
Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9498-0 · Cited by 316
Self-citationHematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally-Raghavan, P., Miyake, T., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 311
Self-citationBest, M. G., Wesseling, P., & Wurdinger, T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0887 · Cited by 297
Platelets reduce anoikis and promote metastasis by activating YAP1 signaling
Haemmerle, M., Taylor, M. L., Gutschner, T., Pradeep, S., Cho, M. S., Sheng, J., Lyons, Y. M., Nagaraja, A. S., Dood, R. L., Wen, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00411-z · Cited by 274
Self-citationPlatelets and cancer angiogenesis nexus
Wojtukiewicz, M. Z., Sierko, E., Hempel, D., Tucker, S. C., & Honn, K. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9673-1 · Cited by 257
Interleukin-6 Stimulates Defective Angiogenesis
Gopinathan, G., Milagre, C., Pearce, O. M. T., Reynolds, L. E., Hodivala-Dilke, K., Leinster, D. A., Zhong, H., Hollingsworth, R. E., Thompson, R., Whiteford, J. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1227 · Cited by 249
Self-citationPlatelets increase the proliferation of ovarian cancer cells
Cho, M. S., Bottsford-Miller, J., Vasquez, H. G., Stone, R., Zand, B., Kroll, M. H., Sood, A. K., & Afshar-Kharghan, V. (2012) · Blood · doi:10.1182/blood-2012-06-438598 · Cited by 245
Self-citationBiologics for targeting inflammatory cytokines, clinical uses, and limitations
Rider, P., Carmi, Y., & Cohen, I. (2016) · International Journal of Cell Biology · doi:10.1155/2016/9259646 · Cited by 226
Stapley, S., Peters, T. J., Neal, R. D., Rose, P. W., Walter, F. M., & Hamilton, W. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.190 · Cited by 183
Saha, B., Mathur, T., Tronolone, J. J., Chokshi, M., Lokhande, G. K., Selahi, A., Gaharwar, A. K., Afshar-Kharghan, V., Sood, A. K., Bao, G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg5283 · Cited by 90
Self-citationPlatelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance
Hoffmeister, K. M., & Falet, H. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30370-x · Cited by 86
Novel mechanisms of platelet clearance and thrombopoietin regulation
Grozovsky, R., Giannini, S., Falet, H., & Hoffmeister, K. M. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000170 · Cited by 66
Siltuximab (CNTO 328): a promising option for human malignancies
Chen, B.-A., & Chen, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86438 · Cited by 65
Saha, B., Mathur, T., Handley, K. F., Hu, W., Afshar-Kharghan, V., Sood, A. K., & Jain, A. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001632 · Cited by 63
Self-citationLucia, A., & Ramírez, M. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1606456 · Cited by 53
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Metadata
- Authors
- Stone, R. L., Nick, A. M., McNeish, I. A., Balkwill, F., Han, H. D., Bottsford-Miller, J., Rupaimoole, R., Armaiz-Pena, G. N., Pecot, C. V., Coward, J., Deavers, M. T., Vasquez, H. G., Urbauer, D., Landen, C. N., Hu, W., Gershenson, H., Matsuo, K., Shahzad, M. M. K., King, E. R., Tekedereli, I., Ozpolat, B., Ahn, E. H., Bond, V. K., Wang, R., Drew, A. F., Gushiken, F., Lamkin, D., Collins, K., DeGeest, K., Lutgendorf, S. K., Chiu, W., Lopez-Berestein, G., Afshar-Kharghan, V., & Sood, A. K.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Queen Mary University of London (GB)
- University of Alabama at Birmingham (US)
- University of Maryland, Baltimore (US)
- University of Cincinnati (US)
- University of Iowa Holden Comprehensive Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-16
- Volume
- 366
- Issue
- 7
- Pages
- 610-618
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3296780
- OpenAlex
- W2117600467
- Cited by
- 812
- References
- 26
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 71 · 2023: 53 · 2022: 81 · 2021: 58 · 2020: 64 · 2019: 50 · 2018: 55 · 2017: 81 · 2016: 58 · 2015: 58 · 2014: 47 · 2013: 28 · 2012: 23
- FWCI
- 33.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Funders
- U.S. Department of Defense (RC2GM092599, U54 CA151668, CA128797, BC085265, OC073399)
- Ovarian Cancer Research Fund
- RGK Foundation
- Queen Mary University of London
- Laura and John Arnold Foundation (BC085265, RC2GM092599, U54 CA151668, CA128797)
- Marcus Foundation
- National Institutes of Health (CA- 016672, BC085265, CA098258, CA083639)
- Medical Research Council
- National Cancer Institute (CA 109298, CA 016672, P50CA098258, U54CA151668, CA 101642, R01CA109298, T32CA009666, CA009666, CA140933, R01CA104825, R01CA140933, R01CA128797, P50CA083639, CA098258, P30CA016672, T32CA101642, CA 128797)
- National Institute of General Medical Sciences (RC2GM092599)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- epithelial ovarian cancer, thrombopoietin, interleukin-6, platelets, tumor growth, angiogenesis, paclitaxel, antiplatelet therapy, survival, paracrine signaling
- MeSH terms
- Interleukin-6 Inhibitors, Animals, Antibodies, Monoclonal, Blood Platelets, Disease Models, Animal, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Paraneoplastic Syndromes, Platelet Count, Thrombocytosis, Thrombopoietin, Signal Transduction, Interleukin-6, Proportional Hazards Models, Mice, Knockout, Disease-Free Survival, Receptors, Interleukin-6, Mice, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.